MedTrace Logo

Treatment of Acute Stroke With Cromolyn(Single Dose)

NCT01175525 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2010-08-05

No results posted yet for this study

Summary

Mastocytes were proven to have a central rule in their development of the lipoid plaque of the vascular system. Mastocytes also has an important role in the stabilisation of the plaque in the building of the brain barrier. Different animal studies show that the inhibition of the mastocyte activity decreases significantly the risk of secondary bleeding post ischaemic stroke.It was also shown that post stroke inflammation process was also blocked by the inhibition of mastocytes.Other studies showed up to 100% decrease in the brain barrier disruption and post stroke oedema, after treatment with mastocyte inhibitors.

Cromolyn is a synthetic drug which has an anti-allergic effect by inhibition of the mastocytes. This drug is a well known,safe drug and is the main sub-substance that was used in the previously mentioned studies.

Conditions

  • Acute Stroke

Interventions

DRUG

CROMOLYN

Cromolyn 200mg (dissolved in water) given 4 times a day

DRUG

sugar pill

sugar pill Dissolved in water taken 4 times daily 30 minutes prior to meals

Sponsors & Collaborators

  • Wolfson Medical Center

    lead OTHER_GOV

Principal Investigators

  • Yair Lampl, Neurologist · Wolfson Medical Center

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01175525 on ClinicalTrials.gov